Legend Biotech Corporation
LEGN
$34.18
-$0.52-1.50%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Net Income | -101.46% | 90.86% | 46.66% | -6.58% | 26.78% |
Total Depreciation and Amortization | 10.40% | 8.03% | 11.07% | 10.81% | 9.03% |
Total Amortization of Deferred Charges | -37.07% | 212.82% | 7.14% | -43.63% | -39.52% |
Total Other Non-Cash Items | 5,009.75% | -100.15% | -7,916.85% | 103.33% | 97.43% |
Change in Net Operating Assets | -579.19% | 142.57% | 433.65% | -121.57% | -104.54% |
Cash from Operations | -24.61% | 98.31% | 111.15% | -92.28% | 15.62% |
Capital Expenditure | 61.60% | 43.87% | -46.12% | 33.69% | -108.57% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 262.57% | -499.10% | -2,025.16% | 1,208.10% | -256.12% |
Cash from Investing | 257.40% | -471.67% | -2,570.98% | 1,534.48% | -263.48% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | 32.36% | 23.88% | 6.88% | 121.61% | -144.81% |
Issuance of Common Stock | 101.68% | -99.73% | 329.46% | -0.48% | -99.29% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 341.73% | -99.88% | 287.16% | 218.14% | -99.75% |
Foreign Exchange rate Adjustments | 166.84% | -99.62% | 85.43% | 231.11% | -43.33% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 195.66% | -221.49% | -201.75% | 1,276.85% | -162.30% |